Adenomyosis

Adenomyosis — endometrial glands growing within the uterine muscle — impairs implantation and IVF outcomes, but targeted strategies significantly improve success rates.

Estimated in 20–35% of reproductive-age women; present in up to 40% of infertile women evaluated by MRI

Defined as endometrial glands and stroma embedded within the myometrium, causing uterine enlargement and abnormal peristalsisDiagnosed by transvaginal ultrasound (myometrial heterogeneity, asymmetric thickening) or MRI (junctional zone thickness > 12 mm)Frequently co-exists with endometriosis (20–80% overlap) and uterine fibroidsAssociated with dysmenorrhea, heavy menstrual bleeding, and pelvic pain — but up to 35% of cases are asymptomaticGnRH agonist suppression for 3–6 months before frozen embryo transfer is associated with significantly improved IVF outcomes

Find Clinics That Specialize in Adenomyosis

How Adenomyosis Affects Fertility

Adenomyosis impairs fertility through multiple mechanisms centered on the disrupted uterine environment. The junctional zone — the inner myometrial layer that regulates uterine peristalsis — is thickened and dysregulated in adenomyosis, producing abnormal contractility patterns that interfere with sperm transport, implantation, and early embryo retention. Abnormal peristalsis has been directly observed on cine-MRI in women with adenomyosis, with contractions oriented against the normal fundal direction during the implantation window. At the molecular level, adenomyotic endometrium shows altered expression of implantation markers including HOXA10, integrins, and leukemia inhibitory factor (LIF), all critical for embryo-endometrial dialogue.

The impact of adenomyosis on IVF outcomes has been increasingly characterized in large retrospective studies and meta-analyses. A systematic review by Vercellini et al. (Fertil Steril 2014) found that adenomyosis was associated with a 28% reduction in clinical pregnancy rate and a 30% reduction in live birth rate per IVF cycle compared to controls. A more recent meta-analysis (Younes & Tulandi, J Minim Invasive Gynecol 2017) confirmed lower implantation, clinical pregnancy, and live birth rates, with higher miscarriage rates. However, these reductions are clinically significant but not prohibitive — many women with adenomyosis conceive successfully with IVF, particularly with optimized protocols.

Focal adenomyosis (adenomyoma) is a circumscribed adenomyotic mass within the myometrium that may mimic a fibroid on imaging. Diffuse adenomyosis involves widespread myometrial infiltration and is generally associated with worse fertility outcomes than focal disease. The severity of junctional zone disruption on MRI correlates with reproductive outcomes. Importantly, adenomyosis frequently co-exists with endometriosis, and both conditions must be addressed together in the treatment plan.

Treatment Options

Treatment is individualized based on age, severity, duration of infertility, and partner factors. Work with your reproductive endocrinologist to determine the right sequence for your specific situation.

First-line treatment

GnRH Agonist Down-regulation Before FET

A 3–6 month course of a GnRH agonist (e.g., leuprolide acetate 3.75 mg monthly) before a frozen embryo transfer (FET) cycle suppresses adenomyosis activity, reduces uterine volume, normalizes junctional zone thickness, and improves endometrial receptivity. Multiple retrospective studies and a meta-analysis (Niu et al., Arch Gynecol Obstet 2013) demonstrate significantly higher implantation and clinical pregnancy rates with GnRH agonist pre-treatment versus no pre-treatment. This is the most evidence-supported intervention for improving IVF outcomes in adenomyosis.

Typical success rate

Clinical pregnancy rate improved 2–3× compared to no pre-treatment in retrospective series

First-line treatment

Freeze-All IVF Strategy with Deferred FET

Because adenomyosis impairs endometrial receptivity in stimulated IVF cycles — particularly through elevated estrogen levels and abnormal peristalsis — a freeze-all strategy followed by a programmed or natural FET cycle is strongly preferred over fresh embryo transfer. Freezing all embryos from the retrieval cycle and deferring transfer to a subsequent optimized cycle allows GnRH agonist pre-treatment, better endometrial preparation, and normalization of the uterine environment. Most fertility centers now adopt this approach as standard for adenomyosis patients.

Adenomyomectomy (Focal Adenomyosis)

Surgical excision of a focal adenomyoma may improve fertility outcomes in selected patients with significant focal disease, particularly when the lesion is large, distorting the uterine cavity, or associated with recurrent implantation failure. However, adenomyomectomy carries risks including uterine rupture during subsequent pregnancy (particularly with deep myometrial excision), reduced uterine volume, and surgical adhesions. ASRM and ESHRE recommend a thorough benefit-risk discussion, with cesarean delivery recommended after adenomyomectomy. Surgery should only be performed by experienced surgeons at centers with high case volumes.

Typical success rate

Improved IVF outcomes in selected patients; evidence limited to observational studies

Dienogest or Progestin Suppression

Oral progestins — particularly dienogest (2 mg/day) — suppress adenomyosis activity by inducing decidualization and atrophy of ectopic endometrial tissue. Dienogest significantly reduces dysmenorrhea, uterine volume, and junctional zone thickness with 3–6 months of pre-treatment. Unlike GnRH agonists, it does not suppress estrogen to menopausal levels and is well tolerated. It is particularly useful for patients who cannot tolerate GnRH agonist side effects or in whom bone density is a concern. Contraceptive effect requires washout period before IVF.

Supportive IVF Optimization

In addition to hormonal pre-treatment, IVF protocol adjustments improve outcomes in adenomyosis. These include careful progesterone monitoring in the luteal phase (elevated progesterone on the day of trigger is associated with poor endometrial receptivity), PGT-A to select euploid embryos (reducing the miscarriage risk that adenomyosis amplifies), and ERA (endometrial receptivity array) testing for patients with recurrent implantation failure to personalize the window of implantation for embryo transfer.

What Patients with Adenomyosis Can Expect

Adenomyosis reduces per-cycle IVF success rates by approximately 28–30% compared to matched controls. However, with GnRH agonist pre-treatment and a freeze-all/FET strategy, outcomes improve substantially — many centers report live birth rates approaching those of non-adenomyosis patients. Severity of disease (diffuse vs. focal, junctional zone thickness) is the strongest predictor of outcome.

Treatment	Typical Success Range	Notes
IVF without pre-treatment (adenomyosis)	25–35% clinical pregnancy rate per transfer	vs. ~40% in matched controls; Vercellini et al., Fertil Steril 2014
IVF with GnRH agonist pre-treatment (3–6 months)	40–55% clinical pregnancy rate per FET	Retrospective series; significant improvement over no pre-treatment
Fresh embryo transfer (adenomyosis)	Lower than FET; not recommended	Abnormal peristalsis and estrogen environment impair receptivity
Freeze-all + programmed FET	35–50% live birth per transfer (with GnRH agonist prep)	Standard approach at most centers for adenomyosis patients

Individual outcomes vary significantly based on age, ovarian reserve, partner factors, and clinic expertise. These figures are based on published research (ASRM, SART, Cochrane Reviews) and national averages — they are not guarantees. Ask your clinic for their own reported outcomes for your specific diagnosis and age group.

Questions to Ask Your Reproductive Endocrinologist

Bring this list to your first consultation to make the most of your appointment.

1
Has adenomyosis been confirmed, and if so, is it focal or diffuse — and how thick is my junctional zone on MRI?
2
Do I also have endometriosis, and how does the combination affect my treatment plan?
3
Do you recommend GnRH agonist pre-treatment before my embryo transfer, and for how long?
4
Should I pursue a freeze-all strategy, and why is fresh transfer less favorable with adenomyosis?
5
Would adenomyomectomy benefit me, and what are the surgical risks including uterine rupture in a future pregnancy?
6
Should I have an ERA (endometrial receptivity analysis) if I have had recurrent implantation failure?

When to See a Specialist

Women with known adenomyosis who are trying to conceive should see a reproductive endocrinologist before starting treatment. If adenomyosis is suspected on pelvic ultrasound — even without confirmed diagnosis — fertility consultation is warranted to plan MRI evaluation and a pre-conception treatment strategy. Women with adenomyosis and prior IVF failures should seek evaluation at a center with adenomyosis-specific protocols.

Ready to Find a Clinic That Specializes in Adenomyosis?

Look for clinics with reproductive endocrinologists (REs) who have documented experience treating Adenomyosis. Ask about their specific outcomes for your diagnosis and age group during your first consultation — outcomes vary significantly by clinic.

Select your state to browse fertility clinics near you:

Browse All Clinics

fertility-health

Thyroid Disorders and Fertility: How Hypothyroidism and Hyperthyroidism Affect Conception

Dr. Carolina GallardoApr 2026

IVF

Beta hCG After IVF: What Your First Result Means

Your first beta hCG result after IVF is one of the most nerve-wracking numbers in the entire process. This guide explains what it means, what doubling times to expect, how to interpret a borderline result, and what comes next.

Dr. Hannah Ní Bhriain RussellApr 2026

IVF

OHSS After IVF: Symptoms, Classification, Prevention & Treatment

Ovarian hyperstimulation syndrome is the most serious complication of IVF stimulation. This guide covers who is at risk, how severity is graded, evidence-based prevention strategies, and what to do if symptoms develop.

Dr. Hannah Ní Bhriain RussellApr 2026

IVF

ICI vs IUI vs IVF: Which Treatment Should You Start With?

The right starting point for fertility treatment is never the same for everyone — it depends entirely on your diagnosis. This guide gives you a clear, evidence-based framework for deciding between ICI, IUI, and IVF.

Prof. Jane HarriesApr 2026